Document is current
Any future updates will be listed below
-
Authors
Inoue, Yusuke
Inui, Naoki
Karayama, Masato
Asada, Kazuhiro
Fujii, Masato
Matsuura, Shun
Uto, Tomohiro
Hashimoto, Dai
Matsui, Takashi
Ikeda, Masaki
Yasui, Hideki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Suda, Takafumi
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical
- License Information
-
More Information
Article History
Received: 5 November 2022
Accepted: 16 April 2023
First Online: 26 April 2023
Declarations
:
: The authors have no conflicts to declare.
: All patients provided written informed consent to participate in the study.
: This study was approved by the institutional review board at each site (Hamamatsu University School of Medicine, #18–164 for the discovery cohort and E16-051 for the validation cohort) and was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. This study was registered at the UMIN Clinical Trials Registry as UMIN000035616 and UMIN000022505.
